Supernus Pharmaceuticals (SUPN) Non Operating Interest Expenses (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has reported Non Operating Interest Expenses for 14 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $2.3 million, a N/A change from a year earlier, with the FY2023 full-year figure at $2.4 million, down 65.84% from the prior year.
• Non Operating Interest Expenses was $2.3 million for Q2 2026 at Supernus Pharmaceuticals, up from $910000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $2.3 million in Q2 2026 and troughed at $910000.0 in Q2 2023.
• A 3-year average of $1.7 million and a median of $1.7 million in 2022 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses plunged 73.14% in 2022 and decreased 22.5% in 2023, its largest moves.
• Over 3 years, Non Operating Interest Expenses stood at $1.6 million in 2022, then plunged by 42.91% to $910000.0 in 2023, then jumped by 154.4% to $2.3 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $2.3 million (Q2 2026), $910000.0 (Q2 2023), and $1.5 million (Q1 2023), per Business Quant data.